Claims for Patent: 6,818,447

Summary for Patent: 6,818,447

Title:	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
Abstract:	The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.
Inventor(s):	Pavco; Pamela (Lafayette, CO), McSwiggen; James (Boulder, CO), Stinchcomb; Daniel (Boulder, CO), Escobedo; Jaime (Alamo, CA)
Assignee:	Sirna Therapeutics, Inc. (Boulder, CO)
Application Number:	09/685,664
Patent Claims:	1. An enzymatic nucleic acid molecule, comprising a sequence complementary to any of the substrate sequences identified as SEQ ID NO:1597, 1641, 1892, 2086, or 2119. 2. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is a ribozyme. 3. The enzymatic nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule is in a hammerhead motif. 4. The enzymatic nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, VS nucleic acid or RNase P nucleic acid motif. 5. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises between 12 and 100 bases complementary to the RNA of KDR receptor. 6. The enzymatic nucleic acid molecule of claim 5, wherein said enzymatic nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA of KDR receptor. 7. A mammalian cell comprising the enzymatic nucleic acid molecule of claim 1, wherein said mammalian cell is not a living human. 8. The mammalian cell of claim 7, wherein said mammalian cell is a human cell. 9. An expression vector comprising nucleic acid sequence encoding one or more of the enzymatic nucleic acid molecules of claim 1. 10. A mammalian cell comprising an expression vector of claim 9, wherein said mammalian cell is not a living human. 11. The mammalian cell of claim 10, wherein said mammalian cell is a human cell. 12. An enzymatic nucleic acid molecule comprising any ribozyme sequence identified as SEQ ID NO:5753, 5797, 6048, 6242, or 6275.

Details for Patent 6,818,447

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-10-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-10-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-10-26